Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Follicular 18Sarcoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, B-Cell 7Rhabdoid Tumor 6Lymphoma, Non-Hodgkin 6Sarcoma, Synovial 5Lymphoma 5Prostatic Neoplasms 4Recurrence 3Mesothelioma 3Lymphoma, Mantle-Cell 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Hematologic Neoplasms 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × tazemetostat × Clear all
NCT03217253 2020-02-07

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡